Clinical Trial to Evaluate the Efficacy of Lacticaseibacillus Rhamnosus CRL1505 in the Prevention of Upper Respiratory Tract Infections in Children
Launched by BIOITHAS SL ·
Trial Information
Current as of November 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a probiotic supplement called Lacticaseibacillus rhamnosus CRL1505 can help prevent upper respiratory tract infections, which are common illnesses like colds that affect the nose, throat, and airways. The study is looking at healthy children to see if taking this probiotic can reduce how often they get these infections.
Children who are eligible to join the trial are those within the age range roughly between 3 and 12 years old. Both boys and girls can participate. If your child joins, they will be randomly given either the probiotic or a placebo (a pill that looks the same but doesn’t have the probiotic) without knowing which one they receive. This helps researchers fairly compare the effects. The trial is currently recruiting participants, so if you have a child in this age group and are interested, this study might be an option to help learn more about preventing common respiratory infections.
Gender
ALL
Eligibility criteria
About Bioithas Sl
Bioithas SL is a leading clinical trial sponsor dedicated to advancing biopharmaceutical research and development. With a focus on innovative therapies, Bioithas SL specializes in conducting Phase I to Phase IV clinical trials, leveraging a robust network of clinical sites and expert investigators. The company is committed to ensuring the highest standards of patient safety and data integrity while facilitating efficient study execution. Through strategic partnerships and a patient-centric approach, Bioithas SL aims to accelerate the delivery of groundbreaking treatments to improve health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Valentina Taverniti
Study Director
Microbes & Health R&D Leader, Centro Sperimentale del Latte S.r.l.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported